Cargando…

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease

In the acute myeloid leukemia (AML) setting, research has extensively investigated the existence and relevance of molecular biomarkers, in order to better tailor therapy with newly developed agents and hence improve outcomes and/or save the patient from poorly effective therapies. In particular, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Maurillo, Luca, Bassan, Renato, Cascavilla, Nicola, Ciceri, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826465/
https://www.ncbi.nlm.nih.gov/pubmed/31548502
http://dx.doi.org/10.3390/cancers11101417
_version_ 1783465093760024576
author Maurillo, Luca
Bassan, Renato
Cascavilla, Nicola
Ciceri, Fabio
author_facet Maurillo, Luca
Bassan, Renato
Cascavilla, Nicola
Ciceri, Fabio
author_sort Maurillo, Luca
collection PubMed
description In the acute myeloid leukemia (AML) setting, research has extensively investigated the existence and relevance of molecular biomarkers, in order to better tailor therapy with newly developed agents and hence improve outcomes and/or save the patient from poorly effective therapies. In particular, in patients with AML, residual disease after therapy does reflect the sum of the contributions of all factors associated with diagnosis and post-diagnosis resistance. The evaluation of minimal/measurable residual disease (MRD) can be considered as a key tool to guide patient’s management and a promising endpoint for clinical trials. In this narrative review, we discuss MRD evaluation as biomarker for tailored therapy in AML patients; we briefly report current evidence on the use of MRD in clinical practice, and comment on the potential ability of MRD in the assessment of the efficacy of new molecules.
format Online
Article
Text
id pubmed-6826465
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68264652019-11-18 Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease Maurillo, Luca Bassan, Renato Cascavilla, Nicola Ciceri, Fabio Cancers (Basel) Review In the acute myeloid leukemia (AML) setting, research has extensively investigated the existence and relevance of molecular biomarkers, in order to better tailor therapy with newly developed agents and hence improve outcomes and/or save the patient from poorly effective therapies. In particular, in patients with AML, residual disease after therapy does reflect the sum of the contributions of all factors associated with diagnosis and post-diagnosis resistance. The evaluation of minimal/measurable residual disease (MRD) can be considered as a key tool to guide patient’s management and a promising endpoint for clinical trials. In this narrative review, we discuss MRD evaluation as biomarker for tailored therapy in AML patients; we briefly report current evidence on the use of MRD in clinical practice, and comment on the potential ability of MRD in the assessment of the efficacy of new molecules. MDPI 2019-09-23 /pmc/articles/PMC6826465/ /pubmed/31548502 http://dx.doi.org/10.3390/cancers11101417 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Maurillo, Luca
Bassan, Renato
Cascavilla, Nicola
Ciceri, Fabio
Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
title Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
title_full Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
title_fullStr Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
title_full_unstemmed Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
title_short Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
title_sort quality of response in acute myeloid leukemia: the role of minimal residual disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826465/
https://www.ncbi.nlm.nih.gov/pubmed/31548502
http://dx.doi.org/10.3390/cancers11101417
work_keys_str_mv AT maurilloluca qualityofresponseinacutemyeloidleukemiatheroleofminimalresidualdisease
AT bassanrenato qualityofresponseinacutemyeloidleukemiatheroleofminimalresidualdisease
AT cascavillanicola qualityofresponseinacutemyeloidleukemiatheroleofminimalresidualdisease
AT cicerifabio qualityofresponseinacutemyeloidleukemiatheroleofminimalresidualdisease